<DOC>
	<DOCNO>NCT00541073</DOCNO>
	<brief_summary>RATIONALE : Pemetrexed may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving pemetrexed together cisplatin vitamin B12 may kill tumor cell . PURPOSE : This phase II clinical trial study well give pemetrexed together cisplatin vitamin B12 work treat patient mesothelioma chest remove surgery .</brief_summary>
	<brief_title>Pemetrexed , Cisplatin , Vitamin B12 Treating Patients With Mesothelioma Chest That Can Be Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Define individually adapt ( dosage ) protocol pemetrexed disodium , cisplatin , vitamin B12 patient unresectable pleural mesothelioma . Secondary - Determine relationship pharmacokinetic pharmacodynamic parameter ( hematologic nonhematologic ) . - Analyze inter-individual pharmacokinetic variation influence covariables pharmacokinetics pemetrexed disodium . - Analyze impact pharmacogenetic ( MTHFR , TS , GSTpi , ERCC1 , XPD ) variation toxicity pemetrexed disodium . - Validate strategy adapt dosage . OUTLINE : This multicenter study . Patients receive pemetrexed disodium IV 10 minute cisplatin IV 2 hour day 1 . Treatment repeat every 3 week 6 course absence disease progression unacceptable toxicity . Patients also receive vitamin B12 intramuscularly day -7 every 9 week chemotherapy complete . Blood sample collect first third course chemotherapy . Samples analyze pharmacogenetic ( MTHFR , TS , GSTpi , ERCC1 , xPD ) , pharmacokinetic , pharmacological method .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin B 12</mesh_term>
	<mesh_term>Hydroxocobalamin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Inclusion criterion : Histologically confirm pleural mesothelioma Unresectable disease Exclusion criterion : Clinically detect pleural effusion ascites control drainage procedure PATIENT CHARACTERISTICS : Inclusion criterion : WHO performance status 02 Life expectancy &gt; 3 month Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Creatinine clearance &gt; 45 mL/min Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) Transaminases ≤ 3 time ULN ( 5 time ULN liver metastasis ) Not pregnant nursing Fertile patient must use effective contraception 6 month completion study treatment Exclusion criterion : Hypersensitivity pemetrexed disodium excipients Peripheral neuropathy ≥ grade 2 Impossible receive study therapy due geographical , social , familial , psychological reason PRIOR CONCURRENT THERAPY : Inclusion criterion : At least 28 day since prior radiotherapy ( 21 day inject radiotherapy ) Exclusion criterion : Prior chemotherapy Prior yellow fever vaccine Inability discontinue aspirin ( &gt; 1.3 g/day ) NSAIDs 2 day prior , , 2 day day 1 course study therapy Concurrent participation another clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>advanced malignant mesothelioma</keyword>
	<keyword>recurrent malignant mesothelioma</keyword>
</DOC>